Clinical Trial

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer type). In Part 1b and Part 2, at least two dosing regimens and two dosing regimens by cancer type, respectively, will be selected, and the safety, tolerability, and efficacy of each regimen will be evaluated.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-02-05; most recent amendment 2026-05-25.
Trial Details
NCT Number NCT06248411
Lead Sponsor Kyowa Kirin Co., Ltd.
Conditions Advanced or Metastatic Solid Tumors
Enrollment 189 participants
Start Date 2023-11-01
Primary Completion 2029-10-31 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-27